Arsenic-related DNA copy-number alterations in lung squamous cell carcinomas by Martinez, V D et al.
Arsenic-related DNA copy-number alterations in lung squamous
cell carcinomas
VD Martinez*,1, TPH Buys
2, M Adonis
1, H Benı ´tez
3, I Gallegos
4, S Lam
2, WL Lam
2 and L Gil
1
1Department of Molecular and Cell Biology, Faculty of Medicine, Biomedical Sciences Institute, University of Chile, Independencia 1027, Santiago
8380453, Chile;
2Department of Integrative Oncology, BC Cancer Research Centre, 675 West 10th Avenue, Vancouver, British Columbia, Canada V5Z
1L3;
3Unidad de Anatomı´a Patolo ´gica, Hospital Regional de Antofagasta, Av. Argentina 1962, Antofagasta 1270001, Chile;
4Departamento de
Anatomı´a Patolo ´gica, Hospital Clı´nico Universidad de Chile, Av. Independencia 1027, Santiago 8380453, Chile
BACKGROUND:Lung squamous cell carcinomas (SqCCs) occur at higher rates following arsenic exposure. Somatic DNA copy-number
alterations (CNAs) are understood to be critical drivers in several tumour types. We have assembled a rare panel of lung tumours
from a population with chronic arsenic exposure, including SqCC tumours from patients with no smoking history.
METHODS: Fifty-two lung SqCCs were analysed by whole-genome tiling-set array comparative genomic hybridisation. Twenty-two
were derived from arsenic-exposed patients from Northern Chile (10 never smokers and 12 smokers). Thirty additional cases were
obtained for comparison from North American smokers without arsenic exposure. Twenty-two blood samples from healthy
individuals from Northern Chile were examined to identify germline DNA copy-number variations (CNVs) that could be excluded
from analysis.
RESULTS: We identified multiple CNAs associated with arsenic exposure. These alterations were not attributable to either smoking
status or CNVs. DNA losses at chromosomes 1q21.1, 7p22.3, 9q12, and 19q13.31 represented the most recurrent events.
An arsenic-associated gain at 19q13.33 contains genes previously identified as oncogene candidates.
CONCLUSIONS: Our results provide a comprehensive approach to molecular characteristics of the arsenic-exposed lung cancer
genome and the non-smoking lung SqCC genome. The distinct and recurrent arsenic-related alterations suggest that this group of
tumours may be considered as a separate disease subclass.
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Arsenic is a well-established skin, bladder, and lung carcinogen,
and B40 million individuals worldwide are regularly exposed to it,
mainly through drinking water (Nordstrom, 2002; IARC (Interna-
tional Agency for Research on Cancer), 2004). In the Northern
Chilean region of Antofagasta, the population (B300000 inhabi-
tants) was chronically exposed to arsenic concentrations as high as
870mgl
–1 from 1958 through 1970, with some towns still
registering concentrations of 600mgl
–1 by the year 2000 (Smith
et al, 1998). This has occurred despite international guidelines
placing the maximum tolerable arsenic exposure at 10mgl
–1
(IARC, 2004).
Lung cancer (LC) is the leading cause of cancer-related mortality
worldwide (Jemal et al, 2006). Lung squamous cell carcinomas
(SqCCs) in particular are strongly tied to exposure to tobacco
smoke (Herbst et al, 2008). Lung cancer is also the main cause of
deaths due to arsenic exposure, with this carcinogen acting as the
major aetiological agent in cancers that occur in never smokers
(Mead, 2005). Relative to other histological subtypes of LC, lung
SqCCs are also strongly associated with arsenic exposure (Guo
et al, 2004). Concordantly, rates for this disease in Antofagasta are
the highest in Chile; SqCCs account for approximately two-thirds
of all LC cases in this region (Servicio de Salud Antofagasta, 2000).
By contrast, SqCCs account for B20% of LCs in North America,
where arsenic exposure is absent or limited (Horner et al, 2009).
Since the 1990s, adenocarcinomas (AdCs) have become the
predominant LC cell type especially among never smokers (Samet
et al, 2009). It has become increasingly difficult to obtain SqCCs
from never smokers to study the mechanism of LC development
unrelated to tobacco smoking to understand alternative pathways
to carcinogenesis. Therefore, our arsenic-exposed never smokers
represent a unique resource to study the molecular pathology of
lung SqCCs.
The mechanism by which arsenic causes cancer is still under
investigation. It has been proposed that both genetic and
epigenetic processes are involved (Salnikow and Zhitkovich,
2008). Interestingly, specific DNA copy-number alterations
(CNAs) have been described in bladder cancer cases from different
populations exposed to arsenic in drinking water, including some
from Northern Chile (Moore et al, 2002; Hsu et al, 2008). These
results suggest that these kinds of alterations are likely to have a
central role in the development and progression of some arsenic-
related cancers.
The CNAs are key events in tumour progression (Hanahan and
Weinberg, 2000). These changes have been widely identified
among phenotypically normal individuals (i.e., germline DNA
copy-number variations (CNVs)) (Redon et al, 2006; Wong et al,
2007). The CNAs, as well as CNVs, include gains/losses of DNA
segments, which can potentially disrupt regulation of gene
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sexpression by dosage or positional effects (Feuk et al, 2006). These
alterations have been extensively described in different LC
subtypes (Pei et al, 2001; Powell et al, 2003; Garnis et al, 2005).
Additionally, non-smoking aetiological agents, such asbestos,
exhibit specific CNAs (Nymark et al, 2006; Kettunen et al, 2009).
To date, there have been no attempts to identify CNAs in lung
tumours in which arsenic is thought to be the main aetiological
factor. Moreover, the non-smoking lung SqCC genome has not
been fully evaluated. This is likely a result of the scarcity of such
cases or the difficulties inherent to discriminating arsenic-related
alterations from those induced by other common lung carcinogens
or polymorphic variations.
In this report, we defined arsenic-associated LC CNAs by applying a
whole-genome tiling-path array-based comparative genomic hybridi-
sation (CGH) platform to a rare panel of arsenic-exposed lung SqCCs
collected from a Northern Chilean population (Watson et al, 2007).
We compare the results for these specimens with those derived from a
panel of lung SqCCs from an unrelated population without known
exposure to arsenic. Smoking-associated alterations were subtracted
by in-group comparisons. Germline CNVs associated with the
Northern Chilean population weres u b t r a c t e df r o ma n a l y s i sb y
evaluation of DNA isolated from the blood of unrelated, healthy
patients from the same region. This work represents a comprehensive
genomic analysis of DNA copy-number changes in LCs in which
arsenic is suspected to be the primary aetiological factor. It also
provides molecular insights into the non-smoking lung SqCC genome.
MATERIALS AND METHODS
Accrual of clinical LC samples and DNA extraction from
tumours
A total of 52 cases of lung SqCC were analysed in this study. Twenty-
two formalin-fixed paraffin embedded lung SqCC specimens were
collected from the Regional Hospital of Antofagasta, Northern Chile
(10 corresponding to never smokers and 12 to smokers). Another
p a n e lo f3 0l u n gS q C Ct u m o u r sf r o mp a t i e n t sw i t hah i s t o r yo f
tobacco use and no known exposure to arsenic was processed in a
similar manner (this latter group was diagnosed at the British
Columbia Cancer Agency in Vancouver, Canada). Demographics,
including age, sex, area of residence and so on, were obtained for each
case (Supplementary Material 1), with histological diagnosis con-
firmed by expert pathology review. ‘Never Smoker’ classifications
were made based on information from medical records using
previously defined criteria (Sun et al, 2007). Pathology review served
to determine tumour cell content for each case. Tumour cells were
isolated from tissue cross-sections by either manual or laser-assisted
microdissection depending on tissue heterogeneity. Microdissected
tissue was placed in an SDS solution with proteinase K at 481Ca n d
spiked with additional enzyme twice a day for 72h. DNA was
extracted by a standard phenol: chloroform method, and DNA
concentrations were determined using a NanoDrop Spectrophot-
ometer (NanoDrop Technologies, Houston, TX, USA) (Sambrook
et al, 1989). An independent group of 22 samples of peripheral blood
derived from phenotypically normal individuals who were also
exposed to arsenic (also from Northern Chile) were processed in the
same form. Demographics for these samples were obtained through
personal interview (after reading and signing an informed consent)
and are also shown in Supplementary Material 1. The Ethics
Committee of the Faculty of Medicine of the University of Chile
(case ID: 085-2008) approved the study and the analysis of both
formalin-fixed paraffin embedded samples and interview data.
Array CGH experiments
Genome alteration profiles were generated using the sub-megabase
resolution tiling-set rearray (SMRTr) platform, which is comprised
of 426000 duplicate-spotted BAC clones that span the whole
human genome (Watson et al, 2007). Briefly, 200ng of tumour/
blood or a single-male reference DNA samples was labelled with
2ml (2nmol) of cyanine-3 dCTP or cyanine-5 dCTP (Perkin Elmer
Life Sciences Inc., Boston, MA, USA), respectively. Labelled probes
were incubated for 18h at 371C, purified, precipitated with Cot-1
DNA (Invitrogen, Burlington, Ontario, Canada), and resuspended
in hybridisation buffer. A 10-min denaturing step at 851C followed
and then repetitive sequences were blocked at 451C for 1h. Probe
mixtures were then applied to the SMRTr array surface and
allowed to competitively hybridise for 40h at 451C. Following
hybridisation, slides underwent agitating 451C washes with 0.1 
saline sodium citrate, 0.1% SDS, and then rinses with 0.1  saline
sodium citrate followed by drying with centrifugation.
Imaging and data processing
Post-hybridisation arrays were analysed as previously described
(Watson et al, 2007). Slides were scanned using a charge-coupled
device-based imaging system (arrayWoRx eAuto, Applied Preci-
sion). The spot signal intensity ratios from images were calculated
using the SoftWoRx Tracker Spot Analysis (Applied Precision,
Issaquah, WA, USA). Data were normalised using a previously
described stepwise framework (Khojasteh et al, 2005). Log2 ratios
were plotted using custom SeeGH software (Chi et al, 2008). BAC
clones with variance 40.01 and signal-to-noise ratio o10 were
excluded from further analysis. Additionally, samples with a global
s.d. 40.15 across autosomal BAC clones were not considered.
DNA CNA detection
The CNAs were defined using a previously described heuristic
algorithm (Jong et al, 2004). Frequency of alteration at each clone
on the array was then calculated. Clones uninformative in 410%
of samples were excluded from further experiments. Analysis was
also restricted to autosomes, with any differences based on sex
subtracted from further comparisons. DNA segments showing log2
ratios 40.2 for DNA gains and o 0.2 for losses were considered
as significant. Significant differences in CNA frequency were
evaluated using the Fisher’s exact test. P-values were adjusted
using the Benjamini–Hochberg method in order to control the
false discovery rate (Benjamini and Hochberg, 1995). An adjusted
P-value o0.05 was used as a significance threshold. Single clone
alterations were excluded from further analysis, ensuring that
multiple, neighbouring clones spanned candidate regions. Finally,
visual inspection of normalised data plotted in SeeGH software
validated those identified segments as CNAs.
Gene content
Through a combined analysis of all genome data for these
tumours, we defined minimal common regions (MCRs) of
recurring DNA gain and loss. This approach has been widely used
for CGH data and is useful for refining our list of genes potentially
affected (Tonon et al, 2005; Lockwood et al, 2008). The MCRs were
specifically defined as the minimal region of DNA spanned by two
or more BAC clones exhibiting the higher frequency of DNA gain/
loss across sample set. Gene content and genomic locations at
MCRs were obtained using the Galaxy Platform (http://main.
g2.bx.psu.edu/), based on March 2006 human genome reference
sequence (NCBI Build 36.1) (Giardine et al, 2005).
RESULTS
Differences in CNA patterns among arsenic-exposed and
non-exposed lung SqCCs
We first independently characterised commonly occurring CNAs
on arsenic-exposed and non-exposed groups using a tiling-path
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swhole-genome array CGH platform. The CNAs associated with arsenic
exposure were defined using the framework shown in Figure 1. First,
we sought to identify differences between exposed and non-exposed
groups. To that end, we compared genomic profiles from 22 tumours
taken from individuals with known arsenic exposure in Northern
Chile (12 smokers, 10 never smokers) against profiles from 30 lung
SqCCs obtained from North America (none of this latter panel had
any documented exposure to arsenic). Results are shown in Figure 2.
On the basis of the Fisher’s exact test – and using a Benjamini–
Hochberg-adjusted P-value cutoff of o0.05 – we identified 68 clones
as being different between these groups. These differences could be
related to arsenic exposure,s m o k i n gs t a t u s ,o rC N V s .
Identification of arsenic-related CNAs
To filter out CNAs associated with smoking, genomic profiles from
within the Chilean subset of SqCC tumours were next compared.
Although all of these cases were known to have arsenic exposure,
10 were never smokers and 12 were current/former smokers. First,
we performed a whole-genome comparison between these groups.
Given what is known about recurring genomic alterations in
recurring lung SqCCs, the low frequency of DNA gains at
chromosome 3q among arsenic-exposed never smokers was of
particular interest (Figure 3).
We next focused our analysis on the 68 clones defined as
differentially altered above. The rationale for this approach was that
shared alterations between these two groups should not be linked to
tobacco smoke (i.e., shared alterations would more likely be associated
with either arsenic exposure or CNVs tied to the population of
Antofagasta, Chile). With this approach, 58 BAC clones did not show
significant differences (considering a significance threshold for
Fisher’s exact test at Po0.05). These were retained for further analysis.
With 58 clones now tied to either arsenic exposure or regional
germline CNVs, we next attempted to filter data to only those
Differences could represent
CNAs associated to arsenic,
smoking habits, and/or ethnic-
specific CNVs
Shared CNAs represent alterations
not associated with smoking habits,
but potentially related with arsenic
exposure and/or CNVs
CNVs were discarded by comparing arsenic-
exposed lung SqCC cases with CNVs in
phenotipically normal individuals
Smokers Smokers
Fisher’s exact test/FDR correction (Benjamini–Hochberg)
68 BAC clones exhibiting differences
Smokers
Smokers
Never
smokers
Never
smokers
Fisher’s exact test (differences discarded)
58 BAC clones sharing alterations
Phenotipically
normal individuals
51 did not shown CNVs
-Additional filtering
-Merge of overlapping intervals
Refined list of
CNAs associated to
arsenic exposure
Gene content/
molecular pathways
analysis
Genes/functions
potentially altered
Result
Molecular analysis
(informatic level)
Evaluating similarities
Evaluating differences
Intermediate result
Statistical test
Arsenic-exposed pheriperal blood
samples (Northern Chile)
Arsenic-exposed lung SqCC cases
(Northern Chile)
Legend
Non-exposed lung SqCC cases
(North America)
Never
smokers
Figure 1 Study framework for identifying DNA alterations associated to arsenic exposure. To discover copy-number alterations (CNAs) associated with
arsenic exposure, we initially screened for differences in alteration frequencies between lung squamous cell carcinoma (SqCC) cases from arsenic-exposed
regions (both smokers and never smokers from Northern Chile, n¼22) and non-exposed regions (from North America, n¼30). Comparisons were
performed using the Fisher’s exact test, with P-value corrected for false-discovery rate (FDR). As a result, 68 bacterial artificial chromosome (BAC) clones
were considered to be differentially altered between these groups (corrected P-value o0.05). Differences could be significantly associated with arsenic
exposure, smoking status, or copy-number variations (CNVs) at this stage. In order to filter out smoking-related alterations, cases from arsenic-exposed
smokers and never smokers were next compared. This analysis was restricted to those regions defined by the first comparison (i.e., 68 BAC clones). Shared
alterations were kept for downstream analysis as these would be unlikely to be related to smoking. Fifty-eight clones shared CNAs status between these
arsenic-exposed lung SqCC groups. Next, we filtered out germline CNVs associated with the population in Northern Chile: the status of the 58 BAC clones
defined above was evaluated in genome profiles generated from peripheral blood samples obtained from an independent group of 22 phenotypically normal
individuals who were exposed to arsenic (also from Northern Chile). Any clones identified as CNVs in this normal population were removed from further
analysis. To make our analysis even more robust, we restricted our regions of interest to those alterations that (1) involved multiple, overlapping array clones
and (2) showed log2 ratios 40.2 or o 0.2 for gains and losses, respectively. Eight unique regions of alteration were found to be significantly associated with
arsenic exposure. Genes mapping to these regions (based on NCBI Build 36.1) were then used for molecular pathway analysis and detailed literature reviews
to determine their relevance to cancer and arsenic metabolism.
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salterations associated with arsenic exposure. First, blood was
drawn from an independent, unrelated group of 22 individuals
from the same region of Northern Chile. None of these individuals
had any recorded incidence of LC or other neoplastic processes
and all had been exposed to arsenic in drinking water. DNA
isolated from these individuals was then profiled and analysed in
the same manner described above. Of the 58 clones defined after
our first two analyses, only 7 were detected as CNVs in this
independent sample set (mainly at chromosome 1). This left 51
BAC clones as CNAs associated with arsenic exposure. To further
restrict our analysis to the most robust differences, only regions
spanned by two or more overlapping BAC clones that showed log2
ratios 40.2 or o 0.2 were considered as regions of alteration
(gains and losses, respectively). This reduced the list to 32 BAC
clones and 8 unique regions of CNAs that occurred at higher
frequency in arsenic-exposed lung SqCC cases from Northern
Chile. These CNAs corresponded to seven regions of DNA loss
(chromosome bands 1q21.1, 2p11.2, 2p11.1, 7p22.3, 9q12, 15q26.3,
and 19q13.31) and one region of DNA gain at 19q13.33 (Table 1).
Finally, we investigated the specific genes associated with the
arsenic-related CNAs described above. A total of 31 genes were
present at MCRs of alteration (Table 1). More than half of the
identified genes were located at two regions of arsenic-specific
CNAs detected at 19q. DNA loss at 19q13.31 (which was not
detected among non-exposed or as CNVs) contains eight genes,
which belong to the family of human pregnancy-specific
glycoproteins. On the other hand, some cancer-related genes, such
as POLD1 (DNA polymerase d 1, catalytic subunit), SPIB (Spi-B
transcription factor), and NR1H2 (nuclear receptor subfamily 1,
group H, member 2) were located at 19q13.33, the single region of
DNA gain associated with arsenic-exposed cases.
DISCUSSION
Tobacco exposure is unquestionably the main aetiological factor in
LC. That said, arsenic ingestion through drinking water also
represents a critical cause of LC – particularly lung SqCCs –
(Ferreccio et al, 2000). In this study, we performed a comprehen-
sive high-resolution characterisation of CNAs in lung SqCC with
different records of arsenic exposure. In addition, we have
screened the non-smoking lung SqCC genome. By this approach,
(+) 50% (–) 50%
Chr. 1
Chr. 9
Chr. 17 Chr. 18 Chr. 19 Chr. 20 Chr. 21 Chr. 22
Chr. 10 Chr. 11 Chr. 12 Chr. 13 Chr. 14 Chr. 15 Chr. 16
Chr. 2 Chr. 3 Chr. 4 Chr. 5 Chr. 6 Chr. 7 Chr. 7
Figure 2 Comparison of DNA alteration frequency for lung squamous cell carcinoma (SqCC) from arsenic-exposed vs non-exposed patients. Genome
profiles were generated for 52 lung SqCC biopsies derived from 22 arsenic-exposed smoker and never-smoker patients from Northern Chile (red), and 30
current and ex-smoker North American patients without known arsenic exposure or non-exposure (blue). Data from each patient were aligned and
frequency of DNA gain/loss for each bacterial artificial chromosome (BAC) clone was calculated across the complete sample set. Frequency of alteration
results for exposed and non-exposed SqCC cases have been overlaid in this figure. Results in yellow denote a region of overlapping alteration status in both
groups. The magnitude of red and blue bars represents percentage of samples exhibiting corresponding alteration (0–100%, with blue vertical lines
representing 50% frequency). DNA gains and losses are represented to the right and left of each chromosome, respectively. Analysis was restricted to
autosomes, with any differences based on sex subtracted from further analysis (see Materials and Methods). Chr., chromosome.
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swe have identified recurrent segmental DNA gains and losses in
lung SqCC following arsenic intake through drinking water.
First, we noted a very low frequency of DNA gains at the
terminal portion of chromosome arm 3q for lung SqCCs from
arsenic-exposed patients. This frequency was subsequently found
to be particularly lower among arsenic-exposed never smokers
(arsenic-exposed smokers showed a similar frequency of 3q gain as
non-exposed cases). Indeed, o30% of cases from arsenic-exposed
never smokers exhibited DNA gains at 3q and only at selected
locations (data not shown), which is similar to the frequency
described for lung AdCs (Luk et al, 2001; Pei et al, 2001).
This result is remarkable, as this alteration – especially between
3q26-q29 – is the most widely reported genomic alteration
associated with lung SqCC tumours and cell lines (Tonon et al,
2005; Garnis et al, 2006). Our results suggest that additional
alterations outside of increased 3q dosage may drive the
emergence of lung SqCCs, particularly where the aetiological basis
for disease is not tobacco smoke.
Another key finding of this work was the particular association
of DNA losses with arsenic-exposed lung SqCC. This result is
concordant with previous findings showing that arsenic can induce
multiple large deletions through the creation of reactive oxygen
species (Concha et al, 1998). DNA losses at 1q21.1, 7p22.3, and
19q13.31 were only detected among arsenic-exposed cases,
suggesting that these alterations could have a role in arsenic-
induced lung neoplasia. We also detected a B300kb deletion at
9q12 in nearly two-thirds of samples from arsenic-exposed
patients. This result is striking given that chromosome 9q deletion
has previously been reported at high incidence in bladder tumours
from never-smoker patients in Argentina and Chile who were
exposed to high levels of arsenic (Moore et al, 2002). One of the
genes at 9q12, FOXD4L6, belongs to the forkhead box (Fox) gene
family. Although neither FOXD4L6 nor other members of the FoxD
gene subfamily have been tied to neoplastic processes, several
other Fox genes have been linked to tumourigenesis and cancer
progression (including LC) (Kim et al, 2006). This suggests
that DNA loss at 9q12, particularly of the FOXD4L6 gene, could be
relevant where arsenic exposure is a critical cancer-causing
mechanism.
The only DNA gain associated with arsenic-exposed cases
occurred at 19q13.33, and this alteration was detected for 68.2% of
cases. Interestingly, this alteration occurred at an even higher rate
in tumours from arsenic-exposed never smokers (90% of cases).
This region has previously been described as recurrently altered in
lung AdCs, including as a lung AdCs susceptibility locus
(Yanagitani et al, 2003; Tonon et al, 2005). Moreover, it has been
proposed that allelic imbalance in this region is essential in lung
AdCs arising in non-smoking patients (Wong et al, 2002). Genes
mapping to 19q13.33 have previously been described as altered by
changes in DNA dosage. For example, the SPIB gene has been
described as gained in lung AdCs (Tonon et al, 2005). SPIB has also
been shown to be gained and overexpressed in B-cell-like diffuse
large B-cell lymphoma (Lenz et al, 2008). This region also contains
the POLD1 gene, which codes for the proofreading domain of the
DNA polymerase d complex. POLD1 participates in DNA single-
strand break repair process and has been shown to increase
genomic instability and incidence of epithelial tumours in mice
(Goldsby et al, 2002; Parsons et al, 2007; Venkatesan et al, 2007).
On the basis of this activity, disruption of POLD1 function could
have a significant role in lung tumourigenesis. NR1H2, which also
maps to this region, has been related with spleen lymphoid
hyperplasia in mouse and could also have a role in the emergence
of this particular subset of lung SqCCs (Bensinger et al, 2008).
These data suggest that gain of 19q13.33 may help drive lung
SqCCs in arsenic-exposed individuals via multiple mechanisms,
including activation of oncogenes, increasing genomic instability,
and disrupted DNA repair. Analysis of a larger sample set and cell
model systems is clearly needed to more precisely delineate the
(–) 50% (+) 50%
3q11.2
3q29
Figure 3 Comparison of copy-number alterations (CNAs) frequency at
chromosome region 3q for lung squamous cell carcinomas (SqCCs)
derived from arsenic-exposed smokers and never smokers. Genome
profiles for 22 cases of arsenic-exposed lung SqCC biopsies (12 from
current and ex-smokers and 10 from never smokers) were compared at
chromosome region 3q and visualised using SeeGH software. Frequency of
CNAs results for smokers and never smokers have been overlaid in this
figure. Results for smokers are represented in red; while results for never
smokers are shown in green (yellow denotes a region exhibiting similar
alteration status in both groups). The magnitude of green and red bars
represents percentage of samples exhibiting corresponding alteration (0–
100%, with blue vertical lines representing 50% frequency). DNA gains and
losses are displayed to the right and left of each chromosome, respectively.
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smolecular basis for both arsenic-induced LC and SqCC in never
smokers. Unfortunately, such studies are largely precluded by the
relative rarity of appropriate specimens. In this context, the results
we present here are a key first step in analysing this subset of lung
tumours.
In sum, we have used high-resolution genomic profiling to
identify arsenic-related CNAs in lung SqCC. This has provided
insights into the molecular mechanisms of both arsenic-induced
cancers and non-smoking lung SqCC. Many genomic loci that we
identified as significantly associated with this lung tumour subset
have been previously implicated in cancer processes, including
candidate genes associated specifically in other arsenic-induced
tumours and other LC subtypes. As we analysed DNA samples
from formalin-fixed paraffin embedded biopsies, further molecular
analysis to establish functional significance is not possible.
However, biological information obtained from this exceptionally
uncommon subset of arsenic-exposed lung SqCC cases (especially
those arisen in never smokers) is valuable. Future efforts will be
focused on functional consequences of arsenic-related CNAs,
specifically on genes located at chromosome 19. Taken together,
our data suggest that lung SqCC in arsenic-exposed individuals
could represent a molecularly distinct form of lung SqCCs. Given a
unique set of underlying genomic changes, distinct approaches to
treatment may be appropriate for this patient population.
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